Table 2.
BAFF serum protein and same-day SLE activity: percentage of patients in each of the BAFF categories (low, medium, high) that experience markers of disease activity at their clinical visit
| Variable | Low (<950 pg/mL) (%, n=96) |
Medium (950–1400 pg/mL) (%, n=98) |
High (>1400 pg/mL) (%, n=98) |
p Value | Adjusted p value for age, ethnicity and sex |
|---|---|---|---|---|---|
| PGA >1 | 20 | 15 | 21 | 0.53 | 0.47 |
| SELENA-SLEDAI ≥2 | 52 | 56 | 64 | 0.21 | 0.089 |
| Urine protein:creatinine ratio >0.5 | 12 | 8 | 13 | 0.59 | 0.32 |
| Anti-dsDNA ≥10 (Crithidia) | 18 | 18 | 32 | 0.026 | 0.013 |
| C3 <79 mg/dL | 8 | 11 | 14 | 0.42 | 0.44 |
| C4 <12 mg/dL | 8 | 9 | 12 | 0.63 | 0.77 |
| ESR >20 mm | 45 | 51 | 58 | 0.19 | 0.11 |
BAFF, B cell activating factor; PGA, physician global assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SELENA, Safety of Estrogens in Lupus Erythematosus: National Assessment.